(Reuters) – Boston Scientific Corp. agreed to pay $ 188.7 million to settle claims from most U.S. states that they fraudulently marketed their surgical mesh devices to consumers.
The settlement with 47 states and Washington DC was announced on Tuesday by several state attorneys. Boston Scientific also agreed to describe consumers more safely and the risks of using networks.
Johnson & Johnson and its Ethicon entity reached a similar $ 117 million deal over the entities in 2019, while Becton Dickinson and Co. and its CR Bard unit reached a $ 60 million deal last September.
The units have also been the subject of extensive disputes between women and manufacturers. Lawyers for some of the complainants have estimated that settlements between the industry and more than 1
States accused Boston Scientific of concealing potentially serious risks of using the devices, including chronic pain, urinary tract function and a new onset of incontinence.  "While Boston Scientific provided income for the health of people in need of care, women were endangered," New York Attorney General Letitia James said in a statement.
Boston Scientific stated that the settlement was not an acknowledgment of misconduct. or liability, and was in the best interests of the shareholders. The payment is covered by the existing reserves of Marlborough, Massachusetts-based companies.
In April 2019, the US Food and Drug Administration ordered Boston Scientific and the Danish company Coloplast A / S, the two remaining manufacturers of transvaginal surgical net implants for pelvic floor prolapse, to stop the sale.
It is said that none of the companies showed a reasonable guarantee of safety and efficiency for their devices. Catalog